KR20240149878A - 위암을 치료하는데 사용하기 위한 화합물 - Google Patents

위암을 치료하는데 사용하기 위한 화합물 Download PDF

Info

Publication number
KR20240149878A
KR20240149878A KR1020247020095A KR20247020095A KR20240149878A KR 20240149878 A KR20240149878 A KR 20240149878A KR 1020247020095 A KR1020247020095 A KR 1020247020095A KR 20247020095 A KR20247020095 A KR 20247020095A KR 20240149878 A KR20240149878 A KR 20240149878A
Authority
KR
South Korea
Prior art keywords
formula
pharmaceutically acceptable
alkyl
halo
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247020095A
Other languages
English (en)
Korean (ko)
Inventor
비베크 케이. 비슈누다스
Original Assignee
비피지바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 비피지바이오, 인크. filed Critical 비피지바이오, 인크.
Publication of KR20240149878A publication Critical patent/KR20240149878A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247020095A 2021-11-17 2022-11-17 위암을 치료하는데 사용하기 위한 화합물 Pending KR20240149878A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163280540P 2021-11-17 2021-11-17
US63/280,540 2021-11-17
PCT/US2022/050289 WO2023091590A1 (en) 2021-11-17 2022-11-17 Compounds for use in treating gastric cancer

Publications (1)

Publication Number Publication Date
KR20240149878A true KR20240149878A (ko) 2024-10-15

Family

ID=84887956

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247020095A Pending KR20240149878A (ko) 2021-11-17 2022-11-17 위암을 치료하는데 사용하기 위한 화합물

Country Status (8)

Country Link
US (1) US20250017906A1 (enExample)
EP (1) EP4433051A1 (enExample)
JP (1) JP2024543111A (enExample)
KR (1) KR20240149878A (enExample)
CN (1) CN118488837A (enExample)
AU (1) AU2022390803A1 (enExample)
CA (1) CA3238430A1 (enExample)
WO (1) WO2023091590A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020417293A1 (en) * 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer
WO2024216283A1 (en) * 2023-04-13 2024-10-17 Bpgbio, Inc. Microtubule targeting agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308617B2 (en) * 2016-06-03 2019-06-04 An2H Discovery Limited Triazole benzamide derivatives and the compositions and methods of treatment regarding the same
CA3112191A1 (en) * 2018-09-10 2020-03-19 Berg Llc Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Also Published As

Publication number Publication date
EP4433051A1 (en) 2024-09-25
US20250017906A1 (en) 2025-01-16
JP2024543111A (ja) 2024-11-19
WO2023091590A1 (en) 2023-05-25
CA3238430A1 (en) 2023-05-25
CN118488837A (zh) 2024-08-13
AU2022390803A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
JP5907396B2 (ja) 腫瘍融解症候群の治療薬及び予防薬
AU2009279944B2 (en) Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP)
US12582653B2 (en) Method for treating idiopathic pulmonary fibrosis
KR101585848B1 (ko) 관절염의 치료 방법
JP7125952B2 (ja) 腫瘍を治療するための薬剤の製造におけるｂｔｋ阻害剤との組み合わせでのｅｚｈ２阻害剤の使用
AU2012224499A1 (en) New pyridazinone and pyridone compounds
WO2023091590A1 (en) Compounds for use in treating gastric cancer
JP5924699B2 (ja) 糖尿病の治療薬
EP1885187B1 (en) Methods for treating drug resistant cancer
JP2020518649A5 (enExample)
US20240277722A1 (en) Cancer therapy using a combination of cdk7 inhibitor with an anti-cancer agent
WO2019173505A1 (en) Methods of treating disorders related to glycemic control
CN114075123B (zh) 苄胺类衍生物及其制备方法与用途
CN112876352A (zh) 一种gpr120蛋白受体抑制剂及其制备和应用
JP2010526073A (ja) 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体
AU2024229823B2 (en) Compositions and methods for making and using small molecules for the treatment of health conditions
KR102767443B1 (ko) 퀴녹살린 카르복스아마이드 유도체 및 이를 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 약학적 조성물
WO2025202900A1 (en) Cdk4 inhibitors for use in the treatment of mantle cell lymphoma
CN113966329B (zh) 作为pdl1检查点抑制剂的杂环免疫调节剂
JP2022532194A (ja) Ｐｉ３ｋ阻害剤の結晶多形及びその製造方法
TW201828939A (zh) 糖尿病性腎病之治療藥或預防藥
HK40064686A (en) Method for treating idiopathic pulmonary fibrosis
JPS58203968A (ja) イソカルボスチリル誘導体
HK40063173A (en) Method for treating idiopathic pulmonary fibrosis
JP2008037753A (ja) 掻痒の治療及び／又は予防剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000